| Ytd | -15.49% | |
| 1y | 36.37% |
| Open | 1.25 | Prev Close | 1.24 | Low | 1.18 | High | 1.25 | Mkt Cap | 185.40M |
| Vol | 584.48K | Avg Vol | 1.04M | EPS | -1.11 | P/E | -1.08 | Forward P/E | -5.30 |
| Beta | 0.98 | Short Ratio | 8.43 | Inst. Own | 70.31% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 1.45 | 200-d Avg | 1.59 | 1yr Est | 5.90 |
CHRS News
Coherus Oncology, Inc. (CHRS) Q2 2026 Earnings Call Transcript
Coherus Oncology NASDAQ: CHRS said it is approaching several clinical data disclosures in the second
Coherus Oncology (CHRS) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus
– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – – Clinical data continue to ma
REDWOOD CITY, Calif. , July 22, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), toda
– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQ
Coherus Oncology (CHRS) remains a Buy as I maintain optimism around its advancing immunotherapy pipe
Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript
Coherus Oncology NASDAQ: CHRS said it expects revenue growth for its nasopharyngeal cancer drug LOQT
Coherus Oncology (CHRS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus
– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2
Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as
REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today
Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abou
Shares of Coherus Oncology, Inc. (NASDAQ: CHRS - Get Free Report) have received an average rating of
Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript
Coherus Oncology (CHRS) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus
– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Re
REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), toda
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarte
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the pu
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn
On Thursday, 369 companies hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (NYSE:EDV) is estimat
During Wednesday's session, 212 companies made new 52-week lows.
During Tuesday's morning session, 137 companies made new 52-week lows.
On Thursday, 221 companies hit new 52-week lows.
On Wednesday, 129 stocks made new 52-week lows.
On Friday, 199 companies reached new 52-week lows.
Thursday's session saw 189 companies set new 52-week lows.
Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 pe
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s p
Companies Reporting Before The Bell • Passage Bio (NASDAQ:PASG) is estimated to report earnings for
Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings a
Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for